title: Potential withdrawal of bevacizumab for the treatment of breast cancer.
authors.forename: Alison
authors.initials: A
authors.lastname: Jones
authors.forename: Paul
authors.initials: P
authors.lastname: Ellis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D018579:Patient Selection; D056737:Safety-Based Drug Withdrawals; D014481:United States
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab